Arcadia Biosciences (NASDAQ:RKDA) announced its earnings results on Wednesday. The basic materials company reported ($2.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($1.27), Fidelity Earnings reports. Arcadia Biosciences had a negative return on equity of 157.32% and a negative net margin of 388.94%. The company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.31 million.
Shares of RKDA stock traded down $0.10 during mid-day trading on Friday, hitting $4.10. The company’s stock had a trading volume of 477,500 shares, compared to its average volume of 1,331,318. Arcadia Biosciences has a 52 week low of $1.82 and a 52 week high of $10.40. The company’s fifty day simple moving average is $4.87 and its 200-day simple moving average is $4.83. The company has a market cap of $44.51 million, a PE ratio of -0.77 and a beta of -3.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.09 and a current ratio of 5.29.
In other Arcadia Biosciences news, Director Kevin Comcowich bought 5,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $5.88 per share, for a total transaction of $29,400.00. Following the purchase, the director now directly owns 20,000 shares of the company’s stock, valued at $117,600. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Matthew T. Plavan bought 8,000 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was acquired at an average price of $8.73 per share, for a total transaction of $69,840.00. The disclosure for this purchase can be found here. Insiders bought a total of 33,200 shares of company stock worth $227,886 in the last 90 days. Company insiders own 3.30% of the company’s stock.
Several research analysts have recently weighed in on the company. ValuEngine raised Arcadia Biosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, November 3rd. HC Wainwright reissued a “buy” rating on shares of Arcadia Biosciences in a research report on Monday, August 12th. Finally, National Securities lifted their price objective on Arcadia Biosciences from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th.
About Arcadia Biosciences
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Featured Article: Stochastic Momentum Index (SMI)
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.